Skip to main content

What is mazdutide?

Medically reviewed by Carmen Pope, BPharm. Last updated on May 7, 2025.

Official Answer by Drugs.com

Mazdutide is a long-acting, once-weekly, injectable medicine that is under development for obesity and type 2 diabetes. It is currently undergoing phase 3 clinical trials and is not expected to be submitted for FDA approval until pre-marketing clinical trials have finished, and results have continued to be favorable.

How does mazdutide work?

Mazdutide is a dual glucagon-like peptide 1 receptor agonist (GLP-1RA) and glucagon receptor agonist, the first in its class. By activating both GLP1R and glucagon receptors it helps regulate appetite, metabolism, and improve glucose control. This dual effect appears promising but more clinical trials are needed.

GLP-1 receptors are widely distributed on the beta-cells of the pancreas, brain, and other tissues and are involved in the control of blood sugar levels by enhancing insulin secretion, among other effects. GLP-1 receptor agonists (GLP-1RAs) are already widely used in the treatment of type 2 diabetes because they stimulate insulin synthesis and secretion in a glucose-dependent manner and cause weight loss. They also delay gastric emptying, regulate blood lipid metabolism, reduce fat deposition, and are neuroprotective, anti-infectious, and cardiovascular protective.

Glucagon receptor agonists on their own are not a good therapeutic option because they increase the liver's production of glucose, but if they are combined with GLP-1RAs then they are effective at reducing fat mass and improving glucose tolerance.

What are the side effects of mazdutide?

Clinical trials have so far reported mazdutide to be well tolerated with mild side effects such as:

How is mazdutide administered?

Mazdutide is administered using a prefilled autoinjector and is given subcutaneously (under the skin), usually in the stomach area, once a week.

Related questions

How effective is mazdutide?

Mazdutide is currently undergoing phase 3 clinical trials to assess its effectiveness.

A phase 2 study of 80 adults who received 9mg mazdutide once a week for 24 weeks reported:

A phase 2 study of 248 participants randomized to receive one of 3 dosing schedules for mazdutide reported:

A phase 1b trial (Ji et al., 2022) of 24 patients (8 received mazdutide 9mg, 8 received mazdutide 10mg, and the rest placebo) reported:

Who makes mazdutide?

Mazdutide is manufactured by Innovent Biologics under a licensing agreement with Eli Lilly and Company (Lilly).

Is mazdutide known by any other name?

Mazdutide is also known as OXM3.

References
  • Pocai, A., Carrington, P. E., Adams, J. R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M. E., Jiang, G., Liu, F., Miller, C., Tota, L. M., Zhou, G., Zhang, X., Sountis, M. M., Santoprete, A., Capito', E., Chicchi, G. G., Thornberry, N., … SinhaRoy, R. (2009). Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes, 58(10), 2258–2266. https://doi.org/10.2337/db09-0278
  • Ji, L., Gao, L., Jiang, H., Yang, J., Yu, L., Wen, J., Cai, C., Deng, H., Feng, L., Song, B., Ma, Q., & Qian, L. (2022). Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomized, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinical Medicine, 54, 101691. https://doi.org/10.1016/j.eclinm.2022.101691
  • Innovent Announces Phase 2 Study of Mazdutide(IBI362) in Chinese Participants with Overweight or Obesity Met Primary and All Key Secondary Endpoints Cision R Newswire. Jun 07, 2022. https://www.prnewswire.com/news-releases/innovent-announces-phase-2-study-of-mazdutideibi362-in-chinese-participants-with-overweight-or-obesity-met-primary-and-all-key-secondary-endpoints-301562931.html
  • Innovent Announces First Participant Dosed in Phase 3 Clinical Study (GLORY-1) of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity. Nov 14, 2022, 19:00 ET Cision PR Newswire https://www.prnewswire.com/news-releases/innovent-announces-first-participant-dosed-in-a-phase-3-clinical-study-glory-1-of-mazdutide-ibi362-in-chinese-adults-with-overweight-or-obesity-301676778.html
  • Pocai, A., Carrington, P. E., Adams, J. R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M. E., Jiang, G., Liu, F., Miller, C., Tota, L. M., Zhou, G., Zhang, X., Sountis, M. M., Santoprete, A., Capito', E., Chicchi, G. G., Thornberry, N., … SinhaRoy, R. (2009). Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes, 58(10), 2258–2266. https://doi.org/10.2337/db09-0278

Read next

Zepbound Vs Mounjaro: Complete Comparison Guide for Weight Loss and Diabetes Treatment

Comprehensive comparison of Zepbound vs Mounjaro. Learn about their uses, dosing, effectiveness, costs, and safety profiles to understand which medication might be right for you. Continue reading

Ozempic Side Effects to Watch For

The most common Ozempic side effects with Ozempic include stomach problems, like nausea, vomiting, diarrhea, stomach pain and constipation. These tend to be mild-to-moderate and usually clear up in a few weeks in most people. Low blood sugar (hypoglycemia) is also a common side effect (when used with certain other diabetes treatments) and it can be serious. Continue reading

Why am I not losing weight on Mounjaro?

It takes time, about 8 to 12 weeks to see a 6% to 8% weight loss in adults using Mounjaro. Other reasons include the need to follow a reduced calorie diet and exercise program, your dose may need to be increased, or side effects may affect your treatment. Continue reading

See also:

Related medical questions

Related support groups